BIOCORP : Acquisition by Novo Nordisk - Management contact - Hold (3) vs Strong Buy (1), Target Price: 35.0€ Price: 34.0€ at 16/06/23 BIOSENIC: Failure of ALLOB phase 2b trial inherited from Bone Therapeutics - Strong Buy (1), Target Price: €0.35 Price: €0.11 on 16/06/23 MITHRA: Reduce its stake in Mayne Pharma - Strong Buy (1), Target Price: 4.10€ Price: 2.63€ at 16/06/23
BIOCORP : Acquisition par Novo Nordisk – Contact Dirigeant – Conserver (3) vs Acheter (1), obj. 35.0€ Cours: 34.0€ au 16/06/23 BIOSENIC : Échec de l’essai de phase 2b ALLOB hérité de Bone Therapeutics – Acheter (1), obj. 0.35€ Cours: 0.11€ au 16/06/23 MITHRA : S’allège de Mayne Pharma – Acheter (1), obj. 4.10€ Cours: 2.63€ au 16/06/23
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
BIOCORP - CORPORATE | EUR33 VS. EUR32 (+10%) Eyes turned towards Mallya’s launch this year 2020 results in line with our expectations 2021: the year of Mallya’s launch Biocorp is more and more a connected device company Positive outlook reiterated
BIOCORP - CORPORATE | EUR32 vs. EUR25 (+27%) A new agreement with Roche France - FV increased to EUR32 Second big diabetes player to sign with Biocorp Mallya the device of choice for insulin pens EUR100m peak sales for Mallya Higher chances of reaching peak sales - FV increased to EUR32
Biocorp a pharmaceutical devices specialist. Created in 2004, the group manufactures traditional medical devices (such as stoppers, droppers etc.) for big players such as Sanofi and has also developed a range of innovative products to improve liquid transfer or to protect patients from needles during injections. Biocorp has signed several agreements to develop and manufacture new devices which should generate about EUR5m/year in sales starting in 2021.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.